Cidara Therapeutics (CDTX) Proxy Filing summary

Executive summary

• Annual Meeting scheduled for July 18, 2024, with voting open until July 17, 2024, 11:59 PM ET.

• Shareholders can access proxy materials online or request paper/email copies by July 4, 2024.

• Meeting will be held virtually, allowing remote participation and voting.

Voting matters and shareholder proposals

• Election of three Class III directors: Carin Canale-Theakston, James Merson, Ph.D., and Chrysa Mineo.

• Proposal to amend the Certificate of Incorporation to increase authorized common stock from 20,000,000 to 50,000,000 shares.

• Approval of any change of control from Series A Preferred Stock conversion, per Nasdaq rules.

• Approval of the 2024 Equity Incentive Plan.

• Ratification of Ernst & Young LLP as independent auditor for fiscal year ending December 31, 2024.

• Advisory vote on executive compensation (say-on-pay).

• Approval to adjourn the meeting if more time is needed to solicit votes for Proposals 2 or 3.

Board of directors and corporate governance

• Board recommends voting in favor of all proposals and director nominees.

• Board oversight includes director elections and governance of equity and compensation plans.